- Published on
KembaraXtra-Medicine – Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia (ALL) is a malignant disorder of immature lymphoid precursor cells (lymphoblasts) derived from either B-cell or T-cell lineages. It is characterized by uncontrolled proliferation of these malignant lymphoblasts with progressive replacement of normal bone marrow elements, leading to bone marrow failure and peripheral cytopenias. A related entity, lymphoblastic lymphoma (LBL), is diagnosed when disease is primarily extramedullary—most commonly presenting as a mediastinal mass in T-cell disease—and bone marrow involvement is less than 20%. ALL is also called acute lymphocytic leukemia or acute lymphoblastic leukemia and is coded under ICD-10-CM as C91.00 (not having achieved remission), C91.01 (in remission), and C91.02 (in relapse).
ALL is predominantly a disease of children, adolescents, and young adults. The overall incidence is approximately 1.8 per 100,000 persons per year, and about 65% of cases occur in individuals younger than 34 years. It is most commonly diagnosed before age 20 based on SEER data (2015–2019). Incidence varies by race and ethnicity, being more common in Hispanics and whites than in blacks. There is a slight male predominance with a male-to-female ratio of approximately 55:45.
Clinical presentation is typically driven by marrow infiltration and failure, producing symptoms of anemia, thrombocytopenia, and neutropenia. Patients may develop fatigue, pallor, weakness, and shortness of breath from anemia; petechiae, bruising, and bleeding from thrombocytopenia; and fever that may be due to the leukemia itself or secondary infection. Bone pain is common and reflects leukemic infiltration of bones or expansion of the marrow cavity. Many patients have lymphadenopathy or hepatosplenomegaly. Central nervous system involvement may cause neurologic deficits, altered mental status, or other neurologic symptoms. T-cell LBL is classically associated with a mediastinal mass, which can produce respiratory distress and superior vena cava syndrome and requires special precautions because sedation can worsen airway compromise if tracheal compression is present.
Most cases of ALL occur sporadically without clearly established risk factors. Ionizing radiation exposure is a recognized risk factor. Down syndrome (trisomy 21) is associated with an increased leukemia risk of roughly 3% by age 30, predominantly ALL. ALL may also occur in other hereditary premalignancy syndromes such as ataxia-telangiectasia.
The differential diagnosis depends on the clinical context and the presence of lymphocytosis or circulating blasts. In adults with lymphocytosis, disorders such as chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and hairy cell leukemia must be considered. In adolescents and young adults, infectious mononucleosis syndromes caused by Epstein–Barr virus or cytomegalovirus can cause reactive lymphocyte abnormalities that may appear blast-like. Disorders that may produce circulating blasts or blast-like cells include acute myeloid leukemia, prolymphocytic leukemia, blastoid mantle cell lymphoma, and Burkitt lymphoma (mature B-cell leukemia/lymphoma). Lymphoblastic lymphoma is also closely related and may overlap clinically. Aplastic anemia is an important “don’t miss” alternative, especially because ALL may rarely present without circulating blasts and instead appear as isolated marrow failure.
Diagnosis requires demonstration of an abnormal lymphoblast population and full biologic risk characterization. Flow cytometry is central to lineage assignment and typically identifies B-lineage blasts through CD19 with cytoplasmic CD22 and/or cytoplasmic CD79a, while immature blasts commonly express CD10, CD34, and terminal deoxynucleotidyltransferase (TdT) with absent surface immunoglobulin. Strong CD20 expression, surface immunoglobulin positivity, and TdT negativity should prompt evaluation for mature B-cell neoplasms such as Burkitt leukemia/lymphoma because this distinction critically changes treatment. T-lineage blasts are typically confirmed by cytoplasmic CD3 and CD7. Aberrant myeloid marker expression such as CD13 or CD33 can occur. Early T-cell precursor ALL (ETP-ALL) has a distinct immunologic signature and is clinically important because it carries different prognostic implications and may require different treatment approaches. Cytochemical stains are less specific but may be available quickly; ALL blasts should be negative for myeloperoxidase and esterase stains. A bone marrow examination confirms diagnosis and extent of marrow replacement and provides material for cytogenetic and molecular testing.
Genetic studies are essential because they define major treatment categories, especially Philadelphia chromosome–positive (Ph+) versus Philadelphia chromosome–negative (Ph−) ALL. This distinction is urgent because Ph+ ALL requires incorporation of ABL1 tyrosine kinase inhibitors. Ph+ ALL is uncommon in children (about 2%–5%) but becomes increasingly common with age and represents about 20%–25% of adult ALL overall, rising to more than 50% of cases in patients older than 60 years. Ph status should be determined rapidly via PCR or FISH, ideally within 24–48 hours of diagnosis. The WHO recognizes ALL/LBL variants with recurrent cytogenetic abnormalities as distinct syndromes, including BCR-ABL1 (t(9;22)), KMT2A (MLL) rearrangements (often t(4;11)), ETV6-RUNX1 (t(12;21)), hyperdiploidy, hypodiploidy, IL3-IGH (t(5;14)), TCF3-PBX1 (t(1;19)), iAMP21, and others, along with T-lymphoblastic leukemia/lymphoma and rarer NK lymphoblastic neoplasms. Common abnormalities have prognostic and therapeutic implications: BCR-ABL1 requires a tyrosine kinase inhibitor; KMT2A rearrangements often present with very high white blood cell counts and confer poor prognosis with frequent consideration of transplant; ETV6-RUNX1 and hyperdiploidy generally confer favorable prognosis in children; hypodiploidy confers adverse prognosis; and TCF3-PBX1 has mixed risk implications, including higher CNS relapse risk historically and benefit from intensified antimetabolite therapy in some settings.
Genetic profiling for “Philadelphia-like” (Ph-like) ALL and IKZF1 (IKAROS) alterations can further refine prognosis and may reveal opportunities for targeted therapy. Ph-like ALL resembles Ph+ ALL in expression patterns but lacks BCR-ABL1; it often has kinase or cytokine receptor pathway activation through ABL-class fusions (ABL1, ABL2, CSF1R, PDGFRB) that phenocopy BCR-ABL1 or through CRLF2, JAK2, and EPOR alterations activating JAK/STAT signaling. Other implicated pathways include additional kinases and RAS pathway alterations. These results may affect therapy selection, but testing may not be universally available.
Lumbar puncture is typically performed at diagnosis when feasible to assess for CNS involvement and to initiate CNS prophylaxis. This is particularly important because CNS therapy is required for essentially all patients regardless of whether CNS disease is detected. Before lumbar puncture, coagulation testing is important, especially if thrombocytopenia or disseminated intravascular coagulation is suspected. Imaging evaluation commonly includes a chest radiograph to assess for mediastinal mass and to evaluate fever. CT imaging may be needed for specific symptoms, but contrast exposure should be used cautiously in the setting of suspected tumor lysis–related renal risk.
Initial laboratory evaluation generally demonstrates normocytic anemia and thrombocytopenia; leukocyte counts may be low, normal, or high. Peripheral smear often reveals lymphoblasts, but some patients have marrow-only disease without circulating blasts. Baseline blood work must include assessment of renal and hepatic function (e.g., creatinine and bilirubin), blood glucose because glucocorticoids are core components of therapy, and evaluation for spontaneous tumor lysis syndrome with potassium, calcium, phosphate, and uric acid levels. Tumor lysis syndrome is common in ALL and can be present even before therapy is initiated, making it a major early cause of morbidity and potential mortality. Tumor lysis results from release of intracellular potassium and phosphate and breakdown of nucleic acids into uric acid, which can precipitate renal failure. Hyperkalemia can trigger fatal arrhythmias; hyperphosphatemia promotes calcium phosphate deposition in renal tissue and lowers serum calcium, creating risk of neuromuscular irritability, seizures, and dysrhythmia. Laboratory tumor lysis syndrome is defined by the presence of at least two characteristic metabolic abnormalities within 3 days before or 7 days after therapy, while clinical tumor lysis includes complications such as acute kidney injury, arrhythmia, seizure, or symptomatic hypocalcemia. Corrected calcium is calculated as measured calcium plus 0.8 multiplied by (4 minus measured albumin in g/dL).
Management of tumor lysis syndrome centers on preserving renal function and preventing life-threatening electrolyte complications. Recommended measures include vigorous hydration, often approximating 3 liters of normal saline per day when feasible, with alkalinization not recommended. If urine output is inadequate, forced diuresis may be used to maintain a target urine output near 2 mL/kg/hour, and dialysis is used when potassium, phosphate, volume overload, or renal failure cannot be controlled medically. Allopurinol is routinely used for uric acid prevention, with adult dosing up to 800 mg/day and pediatric dosing typically 300–450 mg/m²/day. Rasburicase rapidly reduces uric acid and is often effective with a single dose at 0.2 mg/kg, but it must be avoided in patients with G6PD deficiency. Phosphate binders are commonly administered though their benefit is uncertain. Asymptomatic hypocalcemia is not treated in order to avoid worsening calcium phosphate deposition.
Modern outcomes for ALL are excellent in children, with survival improving dramatically from about 10% to approximately 90% over the past four decades, representing a major success of contemporary oncology. Adult outcomes remain poorer but have improved substantially, with cure rates around 60% to 70% in standard-risk adult patients in recent trials. Adults have particularly benefited from tyrosine kinase inhibitor therapy for Ph+ ALL, which is more prevalent with age and may represent a large fraction of disease in older adults. Hyperleukocytosis (WBC >100,000/µL) is less common in ALL than in some other leukemias, and high lymphocyte counts can sometimes be tolerated. Prednisone and vincristine often provide rapid cytoreduction, and leukapheresis is rarely required, though it may be used in selected cases.
Treatment of Ph− ALL generally proceeds through four core components. Induction therapy aims to achieve remission and commonly includes corticosteroids, vincristine, an anthracycline such as daunorubicin or doxorubicin, asparaginase, and sometimes cyclophosphamide depending on protocol. In patients whose blasts express CD20 in significant proportion, rituximab has demonstrated benefit and is incorporated into therapy. Consolidation therapy consists of intensive chemotherapy aimed at preventing relapse after remission, commonly using high-dose antimetabolites such as methotrexate and cytarabine in combination with other agents. Maintenance therapy is prolonged low-intensity outpatient therapy usually continued for two to three years after consolidation, frequently using the POMP backbone of prednisone, monthly vincristine, methotrexate, and oral 6-mercaptopurine. CNS prophylaxis is universal and typically delivered via intrathecal therapy—methotrexate alone or combined with cytarabine and hydrocortisone—administered through lumbar puncture or an Ommaya reservoir. Cranial radiotherapy is generally avoided due to toxicity and is reserved for high-risk situations such as active CNS disease at diagnosis.
Protocol selection varies by institution and trial availability. In the modern era, adolescents and young adults (often defined as ages 15–39) are frequently treated using pediatric or pediatric-inspired regimens because outcomes historically were superior compared with traditional adult regimens. This has influenced practice patterns such that many younger AYA patients are treated on pediatric-style protocols, either within pediatric services or with adult programs using pediatric-inspired approaches.
Allogeneic hematopoietic stem cell transplantation (HSCT) in first remission remains controversial because chemotherapy outcomes have improved. In general, HSCT is considered when predicted cure likelihood with chemotherapy alone is below roughly 50% to 60%, factoring in age, genetics, minimal residual disease status, and donor availability. Autologous transplantation is rarely used in Ph− ALL and has not shown benefit as a replacement strategy. Large comparative data have shown that allogeneic transplant in first complete remission reduces relapse risk compared with chemotherapy or autologous transplant, and can improve overall survival in standard-risk patients, but treatment-related mortality is higher in older and high-risk groups and can offset relapse reduction benefits.
Risk assessment is increasingly driven by biologic markers and response assessment rather than older clinical groupings alone. High-risk features in contemporary trials include KMT2A (MLL) rearrangements, hypodiploidy, persistent minimal residual disease after induction or consolidation, Ph-like genomic signature in Ph− disease, and early T-cell precursor ALL immunophenotype features such as absent CD1a and CD8, weak CD5, and presence of myeloid or stem-cell antigen expression. Prognosis is also influenced by age, presenting white blood cell count, CNS or testicular involvement, cytogenetic abnormalities, and MRD dynamics. MRD is among the strongest predictors: end-of-induction MRD below 0.01% is associated with excellent outcomes, whereas persistent MRD after consolidation predicts very poor prognosis and often leads to consideration of transplant in first remission.
Therapy for Ph+ ALL incorporates an ABL tyrosine kinase inhibitor such as imatinib, dasatinib, nilotinib, or ponatinib combined with chemotherapy. Reported two-year survival rates in Ph+ disease are approximately 50% to 65% across regimens. Some approaches use reduced-intensity induction such as dasatinib with prednisone or imatinib with vincristine and prednisone, achieving very high remission rates while reducing early toxicity and hospitalization. Allogeneic transplantation is often used as consolidation when feasible, though this strategy is increasingly debated with modern TKI-based regimens. Maintenance TKI therapy is typically continued after transplant or after non-transplant therapy.
Relapsed ALL remains challenging. Allogeneic transplantation is often offered, but relapse after transplant is common and long-term cure rates have historically been low near 20%. Newer immunotherapies have transformed outcomes, especially in B-cell ALL. CD19-directed CAR-T therapy has produced very high remission rates in pediatric and young adult patients, with substantial proportions maintaining durable remission at six months, though severe toxicity can occur. Cytokine release syndrome is a major risk and can manifest with vascular leak, hypotension, respiratory and renal failure, coagulopathy, and is treated with tocilizumab, an IL-6 receptor–blocking antibody. Tisagenlecleucel (Kymriah) is a CAR-T product used in pediatric and young adult B-cell ALL, while brexucabtagene autoleucel (Tecartus) is approved for adult relapsed or refractory B-cell ALL based on trials showing meaningful complete response rates, though cytokine release syndrome and neurotoxicity are frequent. Blinatumomab is a bispecific T-cell engager binding CD19 and CD3 that redirects T cells toward leukemia cells and is given as continuous infusion in cycles; it improves remission rates compared with chemotherapy in relapsed settings but responses are not always durable and cytokine release syndrome can occur. Inotuzumab ozogamicin is an anti-CD22 antibody-drug conjugate that produces high remission rates and can bridge patients to transplant, though median remission durations may be limited.
Survivorship care is increasingly important because tens of thousands of childhood and adult ALL survivors now live long-term and are regularly encountered in general practice. Late effects include secondary malignancies related to chemotherapy (often within 5–10 years) and radiation (risk may persist without plateau), cardiomyopathy and heart failure from anthracycline exposure that may emerge decades later, osteopenia and avascular necrosis from glucocorticoid therapy, obesity and metabolic derangements, and neurocognitive deficits. Long-term follow-up commonly includes periodic echocardiography every 3–5 years for asymptomatic cardiomyopathy surveillance, performed more frequently in those with higher anthracycline exposure. Survivors also require screening for malignancy and endocrine disorders in relevant radiation fields if radiation was used, along with proactive monitoring and counseling for obesity and cardiometabolic risk.
0 Comments
